Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot FDA News Management Comments

Heron Therapeutics (HRTX) PT Raised to $66 at Needham & CompanyJune 21, 2018 3:48 PM Two More Positive HTX-011 Studies Supports Bullish Heron Therapeutics (HRTX) Thesis - Cantor FitzgeraldJune 21, 2018 10:47 AM Heron Therapeutics (HRTX) Says HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDAJune 21, 2018 8:05 AM Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast AugmentationJune 21, 2018 8:00 AM